Treating HIV during pregnancy: An update on safety issues

Drug Safety

Volumn 29, Issue 6, 2006, Pages 467-490

  Watts, D Heather ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOLIC ACID ANTAGONIST; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE; PROPYLENE GLYCOL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; SULFONAMIDE; TENOFOVIR; TIPRANAVIR; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BIRTH DEFECT; BLEEDING; BLOOD TOXICITY; BONE DENSITY; BONE MARROW SUPPRESSION; CANCER RISK; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DANDY WALKER SYNDROME; DIARRHEA; DISEASE EXACERBATION; DISEASE TRANSMISSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ANTAGONISM; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FATTY LIVER; FEBRILE CONVULSION; FOLLOW UP; GLUCOSE INTOLERANCE; HEADACHE; HEART DILATATION; HEMOPHILIA; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; KIDNEY FAILURE; LACTIC ACIDOSIS; LIPID STORAGE; LIVER FUNCTION TEST; LIVER TOXICITY; MOTHER FETUS RELATIONSHIP; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHUMAN; ORAL PARESTHESIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PR INTERVAL; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL EXPOSURE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TERATOGENICITY; UNPLEASANT DREAM; VERY LOW BIRTH WEIGHT; VOMITING;

ANIMALS; ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DOGS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREGNANCY OUTCOME; RABBITS; RATS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33744963544     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200629060-00002     Document Type: Review

References (104)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29: 484-94
2. Minkoff H, Ahdieh L, Watts DH, et al. The relationship of pregnancy to the use of highly active antiretroviral therapy. Am J Obstet Gynecol 2001; 184: 1221-7
3. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80
4. Dorenbaum A, Cunningham CK, Gelber RD, et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 2002; 288: 189-98
5. European Collaborative Study. Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 40: 458-65
6. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov/guidelines/ [Accessed 2005 Apr 7]
7. Centers for Disease Control and Prevention. USPHS task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States [online]. Available from URL: http: //aidsinfo.nih.gov/ guidelines/ [Accessed 2005 Mar 24]
8. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991; 163: 226-32
9. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I PACTG Study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-6
10. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus infected pregnant women and their neonates: an AIDS Clinical Trials Group study. J Infect Dis 1999; 180: 1536-41
11. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33
12. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of d4T in combination with 3TC in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group Protocol 332. J Infect Dis 2004; 190: 2167-74
13. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538-9
14. Hitti J, Frenkel L, Stek AM, et al. for the PACTG 1022 study team. Toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. JAIDS 2004; 36: 772-6
15. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7: 255-60
16. Nightingale SL. From the food and drug administration. JAMA 1998; 280: 1472
17. The Antiretroviral Pregnancy Registry: interim report. 1/1/89-1/31/05; issued May, 2005 [online]. Available from URL: www.APRegistry.com [Accessed 2005 Jul 1]
18. Acosta EP, Zorilla C, Van Dyke R, et al. and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2: 460-5
19. Acosta EP, Bardeguez A, Zorilla CD, et al. and the Pediatric AIDS Clinical Trials Group 386 Protocol Team. Pharmacokinetics of saquinavir plus low-dose ritonavir in HIV-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430-6
20. Hayashi S, Beckerman K, Homma M, et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. AIDS 2000; 14: 1061-2
21. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76: 588-97
22. World Health Organization. Antiretroviral drugs for treating HIV infection in resource-limited settings 2005 revisions [online]. Available from URL: http://www.who.int/3by5/mediacentre/news51/en [Accessed 2005 Nov 27]
23. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. African Region 2005 [online]. Available from URL: http://www.who.int/hiv/pub/mtct/en/arvdrugswomenguidelines- final.pdf [Accessed 2005 Nov 27]
24. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. Lancet 1999; 353: 773-80
25. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1: Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med 2000; 343: 982-91
26. Wiktor SZ, Ekpini E, Karon J, et al. Short-course zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353: 781-5
27. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999; 353: 786-92
28. DITRAME ANRS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999; 354: 2050-1
29. Dabis F, Elenga N, Meda N, et al. for the DITRAME Study Group. 18-month mortality and perinatal exposure to zidovudine in West Africa. AIDS 2001; 15: 771-9
30. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised double-blind placebo-controlled trial. Lancet 2002; 359: 1178-86
31. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802
32. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859-68
33. Moodley D, Moodley J, Coovadia H, et al. for the South African Intrapartum Nevirapine Trial (SAINT) Investigators. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725-35
34. Lallemant M, Jourdain G, Le Coeur S, et al. for the Perinatal HIV Prevention Trial (Thailand) Investigators. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217-28
35. Taha TE, Kumwenda NI, Gibbons A, et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362: 1171-7
36. Bucceri AM, Somigliana E, Matrone R, et al. Discontinuing combination antiretroviral therapy during the first trimester of pregnancy: insights from plasma human immunodeficiency virus-1 RNA viral load and CD4 cell count. Am J Obstet Gynecol 2003; 189: 545-51
37. Cruickshank DP, Wigton TR, Hays PM. Maternal physiology in pregnancy. In: Gabbe SG, Neibyl JR, Simpson JL, editors. Obstetrics: normal and problem pregnancies. New York (NY): Churchill Livingstone, 1996
38. Brinkman K, Ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44
39. Martin JL, Brown DE, Mattherws-Davis N, et al. Effects of antiviral nucleoside analogues on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743-9
40. Grimbert S, Fromenty B, Fisch C, et al. Decreased mitochondrial oxidation of fatty acids in pregnant mice: possible relevance to development of acute fatty liver of pregnancy. Hepatology 1993; 17: 628-37
41. Grimbert S, Fisch C, Deschamps D, et al. Effects of female sex hormones on mitochondria: possible role in acute fatty liver of pregnancy. Am J Physiol 1995; 268: G107-15
42. Luzatti R, Del Bravo P, Perri G, et al. Riboflavine and severe lactic acidosis [letter]. Lancet 1999; 353: 901-2
43. Bristol-Myers Squibb. Dear Health Care Provider letter [online]. Available from URL: http://www.fda.gov/medwatch/safety/2001/ zerit&videx_letter.htm [Accessed 2001 Jan 5]
44. Farner L, Sakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78: 58-9
45. Mirochnick M, Dorenbaum A, Holland D, et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21: 835-8
46. Chappuy H, Treluyer J-M, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 2004; 191: 558-62
47. Chmait R, Franklin P, Spector SA, et al. Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance. J Perinatol 2002; 22: 370-2
48. Watts DH, Balasubramanian R, Maupin RT, et al. for the PACTG 316 study team. Maternal toxicity and pregnancy complications in HIV-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol 2004; 190: 506-16
49. Tuomala RE, Watts DH, Li D, et al. for the Women and Infants Transmission Study. Improved obstetrical outcomes and few maternal toxicities are associated with antiretroviral therapy including HAART during pregnancy. JAIDS 2005; 38: 449-73
50. Aschkenazi S, Rochelson B, Bernasko J, et al. Insulin resistance complicating pregnancy in a human immunodeficiency virus-infected patient treated with protease inhibitors and corticosteroids. Obstet Gynecol 2003; 102 (5Pt 2): 1210-2
51. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-7
52. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis 2001; 184: 914-7
53. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 2005 Jan 3; 19 (1): 63-7
54. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. for the Perinatal HIV Prevention Trial Group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004; 351: 229-40
55. Servais J, Lambert C, Karita E, et al. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda. AIDS Res Hum Retroviruses 2004; 20: 279-83
56. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev 2002; 4: 59-63
57. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of Pediatric AIDS Clinical Trials Group protocol 316. J Infect Dis 2002; 186: 181-8
58. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192: 30-6
59. Eshleman SH, Guay LA, Mwatha A, et al. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs 6-8 weeks after single-dose NVP prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 2004; 20: 595-9
60. Sullivan J. South African Intrapartum Nevirapine Trial: selection of resistance mutations [abstract no. LbPeB9024]. XIV International AIDS Conference; 2002 Jul; Barcelona, Spain
61. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38: 283-8
62. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N Nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192: 24-9
63. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192: 16-23
64. Lallemant M. Response to therapy after prior exposure to nevirapine [abstract no. TuFoO205]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24-27; Rio de Janeiro, Brazil
65. Lockman S, Smeaton LM, Shapiro RL, et al. Maternal and infant response to nevirapine (NVP)-based antiretroviral treatment (ART) following peripartum single-does NVP or placebo (Plc) [abstract no. LB5; oral presentation]. 43rd Annual Meeting of the Infectious Disease Society of America; 2005 Oct 6-9; San Francisco (CA)
66. Martinson N, Pumla L, Morris L, et al. Effectiveness of single-dose nevirapine in a second pregnancy [abstract no. 103; oral presentation].12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston (MA)
67. McIntyre J, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus [abstract no. TuFoO204]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24-27; Rio de Janeiro, Brazil
68. Palombi L, Liotta G, Guidotti G, et al. CD4-cell count guided HAART interruption: is it a reliable strategy in resource-limited settings? The DREAM experience [abstract no. WePe12.4C13]. Third International AIDS Society Conference on HIV Pathogenesis and Treatment; 2005 Jul 24-27; Rio de Janeiro, Brazil
69. Watts DH. Management of the HIV-infected pregnancy. N Engl J Med 2002; 346: 1879-91
70. Brocklehurst P, French R. The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis. Br J Obstet Gynaecol 1998; 105: 836-48
71. Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12: 1805-13
72. European Collaborative Study. Is zidovudine therapy in pregnant HIV-infected women associated with gestational age and birthweight? The European Collaborative Study. AIDS 1999; 13: 119-24
73. Lambert JS, Watts DH, Mofenson L, et al. for the Pediatric AIDS Clinical Trials Group 185 Team. Risk factors for preterm birth and low birth weight in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 2000; 14: 1389-99
74. Stratton P, Tuomala RE, Abboud R, et al. Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 1999; 20: 179-86
75. The European Collaborative Study and the Swiss Mother+Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 2913-20
76. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 2337-9
77. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 1863-70
78. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360: 1152-4
79. Frank KA, Buchmann EJ, Schackis RC. Does human immunodeficiency virus infection protect against preeclampsia-eclampsia? Obstet Gynecol 2004; 104: 238-42
80. Mattar R, Amed AM, Lindsey PC, et al. Preeclampsia and HIV infection. Eur J Obstet Gynecol Reprod Biol 2004; 117: 240-1
81. Coll O, Suy A, Martinez E, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20: 59-66
82. Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Inf 2001; 77: 441-3
83. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. JAIDS 2003; 32: 380-7
84. Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-93
85. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al. for the Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17: 2053-61
86. Taha TE, Kumwenda NI, Hoover DR, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292: 202-9
87. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15: 1074-5
88. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782-9
89. Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114: e598-603
90. Newell ML, Borja MC, Peckham C, et al. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics 2003; 111: e52-60
91. Culnane M, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA 1999; 281: 151-7
92. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354: 1084-9
93. Barret B, Tardieu M, Rustin P, et al. for the French Perinatal Cohort Study Group. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17: 1769-85
94. French Perinatal Cohort Study Group. Risk of early febrile seizure with perinatal exposure to nucleoside analogues. Lancet 2002; 359: 583-4
95. Poirier MC, Divi RL, Al-Harthi L, et al. and the Women and Infants Transmission Study. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33: 175-83
96. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18: 1013-21
97. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32: 370-4
98. The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25: 261-8
99. Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343: 759-66
100. Ayers KM, Clive D, Tucker WE, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rates. Fundam Appl Toxicol 1996; 32: 148-58
101. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89: 1602-8
102. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 1997; 38: 195-8
103. Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 463-7
104. Pollock BH, Jenson HB, Leach CT, et al. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA 2003; 289: 2393-9